{"id":178271,"date":"2018-01-17T14:35:02","date_gmt":"2018-01-17T14:35:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=178271"},"modified":"2018-01-17T14:35:02","modified_gmt":"2018-01-17T14:35:02","slug":"irritable-bowel-syndrome-with-constipation-drugs-market-with-industry-size-market-aspect-and-forecast-20172025-acute-market-reports","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/irritable-bowel-syndrome-with-constipation-drugs-market-with-industry-size-market-aspect-and-forecast-20172025-acute-market-reports_178271.html","title":{"rendered":"Irritable Bowel Syndrome with Constipation drugs Market with Industry Size, Market aspect, and Forecast 2017-2025 Acute Market Reports"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Acute Market Reports Logo”<\/div>\n<\/div>\n<\/div>\n
Irritable Bowel Syndrome with Constipation drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022, higher prevalence of IBS in developed world and prompt address to the need for advanced pharmaceutical measures will facilitate the dominance of Europe IBS-C drugs market on the global front.<\/div>\n

IBS is prevalent in general population across the globe for a long period and has affected adversely in terms of medical costs and socioeconomic impact. Increased prevalence of lifestyle related diseases, growth in healthcare spending, augmented patient population suffering from gastrointestinal diseases and medical advancements are the prime contributors to the growth of IBS-C drugs market.<\/p>\n

Browse Here For Full Report: <\/strong>http:\/\/www.acutemarketreports.com\/report\/irritable-bowel-syndrome-with-constipation-drugs-market<\/a><\/p>\n

Europe is a combination of varied market trends mutually prevalent across the comprising countries, attributed by the cultural mix and healthcare infrastructures. The region has the largest share in the global IBS-C drugs market and was valued at USD 445.7 Mn in 2015. As IBS patient pool is the highest in the region, the demand for treatment options is also correspondingly high. The prevalence of IBS in European countries ranges from 5% to 25%.<\/p>\n

IBS and CI are the two most common gastrointestinal disorders in North America. The conditions together affect more than 30 Million individuals as of 2014. North America also has the highest count of patients suffering from constipation. Evolved healthcare infrastructure, early bird commercialization of IBS-C drugs in the US, better reimbursement policies and higher awareness among both physicians and patient population are the major contributors to the dominance of North America in the global market.<\/p>\n

In addition, Asia Pacific is expected to open further avenues for the international players in IBS-C market. APAC is emerging region with the huge scope for the pharmaceutical companies. Japan and China in particular are considered to be very promising countries for drugs market. As Asia is home to half of the world’s population, and offers both a large relatively low-cost workforce in some countries and a potentially huge retail market, this region could be central to the future of the global economy.<\/p>\n

APAC is the third largest market for the drugs of IBS are many big pharmaceutical companies are investing in for future growth. The number of patients suffering from irritable bowel syndrome accounts to almost 7% of the population. China has the largest market share for the drugs manufacturers in this region as this is one of the most potential markets for pharmaceutical giants and largest number of patients after Japan.<\/p>\n

ToC:<\/strong><\/p>\n

Chapter 1 Preface<\/strong>
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Approach Adopted
1.3.5 Key Points<\/p>\n

Chapter 2 Executive Summary <\/strong>
2.1 Market Snapshot: Global Lactic Acid Market<\/p>\n

Chapter 3 Introduction<\/strong>
3.1 Introduction
3.2 Classification
3.3 Drivers
3.4 Restraints
3.5 Opportunities
3.6 Supply Chain
3.7 Porter’s five force analysis
3.7.1 Bargaining power of suppliers
3.7.2 Bargaining power of buyers
3.7.3 Threat of new entrants
3.7.4 Threat of substitutes
3.7.5 Degree of competition………<\/p>\n

Browse Here For Full Report: <\/strong>http:\/\/www.acutemarketreports.com\/report\/irritable-bowel-syndrome-with-constipation-drugs-market<\/a><\/p>\n

About Us:<\/strong>
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.  We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.<\/p>\n

Browse Here For Same Category Reports: <\/strong>http:\/\/www.acutemarketreports.com\/category\/pharmaceutical-market<\/a><\/p>\n

Latest Reports:<\/strong><\/p>\n

http:\/\/www.acutemarketreports.com\/report\/point-of-care-diagnostics-market<\/a><\/p>\n

Web: http:\/\/www.acutemarketreports.com\/<\/a><\/strong><\/em><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Acute Market Reports
Contact Person:<\/strong> Chris Paul
Email:<\/strong> sales@acutemarketreports.com
Phone:<\/strong> Toll Free US\/Canada: +1-855-455-8662
Address:<\/strong>105 N 1st ST #429, SAN JOSE, CA 95103
City:<\/strong> SANJOSE
State:<\/strong> CALIFORNIA
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.acutemarketreports.com\/report\/irritable-bowel-syndrome-with-constipation-drugs-market<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Acute Market Reports Logo” Irritable Bowel Syndrome with Constipation drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022, higher prevalence of IBS in developed world and prompt address to the need for advanced pharmaceutical measures will facilitate the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-178271","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/178271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=178271"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/178271\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=178271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=178271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=178271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}